MYMD - MyMD Pharmaceuticals, Inc. Stock Price and Quote

MYMD [NASD]

Index	-	P/E	-	EPS (ttm)	-0.38	Insider Own	0.60%	Shs Outstand	39.05M	Perf Week	13.16%
Market Cap	72.31M	Forward P/E	-	EPS next Y	-	Insider Trans	4.13%	Shs Float	33.85M	Perf Month	-8.51%
Income	-14.70M	PEG	-	EPS next Q	-	Inst Own	10.70%	Short Float / Ratio	6.10% / 4.69	Perf Quarter	49.57%
Sales	-	P/S	-	EPS this Y	75.20%	Inst Trans	-16.73%	Short Interest	2.06M	Perf Half Y	-32.28%
Book/sh	0.47	P/B	3.66	EPS next Y	-	ROA	-68.00%	Target Price	-	Perf Year	-61.17%
Cash/sh	0.17	P/C	10.18	EPS next 5Y	-	ROE	-76.20%	52W Range	0.90 - 6.15	Perf YTD	49.57%
Dividend	-	P/FCF	-	EPS past 5Y	67.40%	ROI	-	52W High	-72.03%	Beta	2.23
Dividend %	-	Quick Ratio	4.50	Sales past 5Y	-	Gross Margin	-	52W Low	91.11%	ATR	0.21
Employees	9	Current Ratio	4.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	46.71	Volatility	11.05% 12.03%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	34.90%	Profit Margin	-	Rel Volume	1.29	Prev Close	1.70
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	439.67K	Price	1.72
Recom	-	SMA20	-7.10%	SMA50	-12.07%	SMA200	-32.08%	Volume	566,745	Change	1.18%

Mar-20-23 08:55AM	MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF- Inhibitor MYMD-1® in Rheumatoid Arthritis Business Wire -5.00%
Mar-08-23 08:30AM	MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls Business Wire
Mar-02-23 08:30AM	MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD is not a Controlled Substance or Listed Chemical Business Wire +5.62%
Feb-28-23 08:30AM	MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF- Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting Business Wire
Feb-21-23 08:45AM	MyMD Announces $15 Million Offering with Existing Investors Business Wire -7.32%
09:40AM	Loading…
Dec-06-22 09:40AM	ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022 Business Wire -9.74%
Nov-17-22 08:00AM	MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress Business Wire
Nov-14-22 08:00AM	MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research Business Wire -5.96%
Sep-20-22 08:00AM	MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan Business Wire -6.25%
Aug-30-22 08:30AM	MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD Compound Business Wire -7.27%
Aug-03-22 09:45AM	Data Showing MyMD Pharmaceuticals MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences Business Wire
Jul-29-22 09:19AM	Is MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) Popular Amongst Insiders? Simply Wall St. +5.79%
Jul-26-22 07:30AM	MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan Business Wire -11.44%
Jul-12-22 09:30AM	MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions Business Wire +17.10%
Jun-21-22 10:30AM	MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan Business Wire
09:15AM	Loading…
Apr-05-22 09:15AM	MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan Business Wire -8.79%
Mar-24-22 09:26AM	MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24 Business Wire
Feb-23-22 09:15AM	MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan Business Wire -9.49%
Feb-20-22 08:37AM	We're Keeping An Eye On MyMD Pharmaceuticals' (NASDAQ:MYMD) Cash Burn Rate Simply Wall St.
Feb-08-22 09:15AM	MyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan Business Wire -5.13%
Feb-07-22 08:38PM	NorthRock Partners, LLC Buys PepsiCo Inc, iShares MSCI EAFE ETF, iShares MSCI Emerging Markets ... GuruFocus.com
Jan-05-22 09:15AM	MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia Business Wire -5.26%
Dec-29-21 09:15AM	MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia Business Wire
Dec-16-21 10:50AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors PR Newswire
Dec-01-21 10:05AM	MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021 Business Wire
Nov-23-21 09:25AM	MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan Business Wire
Nov-18-21 09:15AM	MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America Business Wire -9.76%
Nov-16-21 09:25AM	MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan Business Wire -11.75%
Nov-15-21 09:45AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors ACCESSWIRE
Oct-26-21 10:30AM	MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation Business Wire
10:30AM	Loading…
Oct-19-21 10:30AM	MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21 Business Wire +6.56%
Oct-05-21 10:00AM	MyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7 Business Wire
Sep-22-21 11:00AM	MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD Business Wire
Sep-13-21 10:00AM	MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan Business Wire -9.30%
Sep-09-21 10:15AM	MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15 Business Wire
Aug-24-21 10:17AM	MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma Business Wire
Aug-23-21 08:47AM	We Think MyMD Pharmaceuticals (NASDAQ:MYMD) Can Afford To Drive Business Growth Simply Wall St. +5.02%
Aug-10-21 02:30PM	MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases Business Wire +13.75%
10:30AM	MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine Business Wire
Aug-05-21 10:30AM	MyMD Pharmaceuticals Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study Business Wire +8.46%
Jul-27-21 09:15AM	MyMD Pharmaceuticals Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis Business Wire
Jul-07-21 09:00AM	MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1 Business Wire -12.50%
Jun-07-21 10:02AM	MyMD Pharmaceuticals Set to Join Russell Microcap® Index Business Wire
May-17-21 09:00AM	MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board Business Wire
May-12-21 09:00AM	MyMD Pharmaceuticals Schedules Business Update Conference Call Business Wire
May-10-21 09:00AM	MyMD Pharmaceuticals: Invitation to the Benzinga Global Small Cap Conference Newsfile
Apr-28-21 10:13AM	Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit Business Wire +10.92%
Apr-22-21 09:20AM	MyMD Pharmaceuticals Announces Issuance of Allowance from United States Patent and Trademark Office for Synthetic Cannabinoid Compounds Business Wire

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rivard Paul	EVP of Operations, GC	Dec 08	Buy	1.53	10,000	15,300	225,000	Dec 08 08:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience